- Home
- OCG vs GLMD Comparison
OCG vs GLMD Comparison
Compare OCG & GLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OCG | GLMD |
|---|---|---|
| Founded | 2018 | 2000 |
| Country | Hong Kong | Israel |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8M | 4.4M |
| IPO Year | 2019 | 2013 |
Fundamental Metrics
Financial Performance| Metric | OCG | GLMD |
|---|---|---|
| Price | $0.57 | $0.52 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.4M | 19.4K |
| Earning Date | 11-14-2025 | 04-02-2026 |
| Dividend Yield | ★ 8.19% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.01 | $0.50 |
| 52 Week High | $19.29 | $2.67 |
Technical Indicators
Market Signals| Indicator | OCG | GLMD |
|---|---|---|
| Relative Strength Index (RSI) | 41.18 | 34.11 |
| Support Level | $0.04 | $0.50 |
| Resistance Level | $0.72 | $0.69 |
| Average True Range (ATR) | 0.12 | 0.05 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 6.45 | 40.65 |
Price Performance
Historical ComparisonAbout OCG Oriental Culture Holding LTD
Oriental Culture Holding Ltd is an online provider of collectibles and artwork e-commerce services. The company also offers online and offline integrated marketing, storage, and technical maintenance services to customers. The company operates through one segment, namely, e-commerce of artwork trading. It generates revenue through listing service fees, transaction fees, and other revenues collected from traders.
About GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.